- Home
- Industry Reports
- Healthcare
- Pharmaceuticals
- Middle East & Africa Biopharmaceuticals Market- Size, Outlook, Trends and Forecast (2024 – 2032)
Biopharmaceuticals are pharmaceutical products which are produced through biotechnology methods involving recombinant DNA techniques, hybridoma techniques, and purification processes. Biopharmaceutical production consists of the use of biological sources, either live organisms or their active components. They are made up of proteins and nucleic acids and target specific diseases and patients groups. Biopharmaceuticals are used in the treatment of various chronic diseases such as cardiovascular, metabolic, neurological, cancer, and other rare diseases for which there are no available treatments.
The Middle East & Africa Biopharmaceuticals Market Segments Size & Growth:
The Middle East & Africa Biopharmaceuticals market size is projected to reach approximately $23.80 billion by the end of 2024 with a CAGR of close to 9.16 % from $15.90 billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include High-profit margins, Huge market demand, Ability of Biopharmaceuticals to treat previously untreatable diseases, Increasing acceptance for Biopharmaceuticals and so on. However, High-end manufacturing requirements, Increasing demand for affordable Biopharmaceuticals and Complicated and Cumbersome regulatory requirements thereby hampering the market growth.
The Middle East & Africa Biopharmaceuticals Market Segments Share:
The Middle East & Africa Biopharmaceuticals Market is categorised into a type which comprises of Monoclonal antibodies, Recombinant growth factors, Purified proteins, Recombinant proteins, Recombinant hormones and so on. Among the Type, a Monoclonal antibodies market segment dominated the Biopharmaceuticals market in 2018 with about 32% share. By Therapeutic Applications, Biopharmaceuticals market is segregated into Neurological diseases, Cardiovascular diseases, Hormonal disorders and so on. Among the Therapeutic Applications, Oncology segment is projected to continue its dominant during the period 2018-2024. By Geography, Africa is expected to dominate the Biopharmaceuticals market and the growth in the Africa economies is mainly attributed because of huge profit margins and growth prospects, biopharmaceuticals have garnered the attention of several large drug development companies.
The Middle East & Africa Biopharmaceuticals Market Trends:
- Biopharmaceuticals currently represent a large segment of product pipelines of most of the major pharmaceutical companies.
- Monoclonal antibodies currently own the most significant market share regarding value in the global biopharmaceuticals market. Some of the top-selling monoclonal antibodies include Adalimumab, Infliximab, Rituximab, and Bevacizumab.
- Amgen is introducing an innovative new value-based pharmacy benefits insurance provision for U.S. staff members. The coverage ensures that any U.S. staff member who is prescribed a clinically appropriate biologic medicine will pay the same out-of-pocket cost as a staff member who has the same condition but does not require a biologic. The benefit was designed to eliminate concerns about cost-related barriers to essential biopharmaceuticals, which play an increasingly prominent role in the treatment of patients with acute illness.
The Middle East & Africa Biopharmaceuticals Market Research Report:
- An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
- To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
- Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
- Identifying DROC in the current market and their impact in altering the market dynamics.
- Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
- Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
- The primary market players, such as
- Merck & Co., Inc.
- Hoffmann-La Roche AG
- Eli Lilly and Company, Inc
- Sanofi
- Amgen Inc
1. Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
4. Market Dynamics
4.1 Drivers
4.1.1 High-profit margins
4.1.2 Huge market demand
4.1.3 Ability of Biopharmaceuticals to treat previously untreatable diseases
4.1.4 Increasing acceptance for Biopharmaceuticals
4.2 Restraints
4.2.1 Complicated and Cumbersome regulatory requirements
4.2.2 High-end manufacturing requirements
4.2.3 Increasing demand for affordable Biopharmaceuticals
4.3 Opportunities
4.3.1 Finding ways of cost reduction
4.3.2 Patent expiry paving the way for Biosimilars
4.4 Challenges
4.4.1 Requirement of cold chain
4.4.2 Scalability limited by several out of hand factors
4.4.3 Extremely difficult development process
5. The Middle East & Africa Biopharmaceuticals Market – By Type
5.1 Monoclonal Antibodies
5.1.1 Anti-Cancer Monoclonal Antibodies
5.1.2 Anti-Inflammatory Monoclonal Antibodies
5.1.3 Other Monoclonal Antibodies
5.2 Recombinant Growth Factors
5.2.1 Erythropoietin
5.2.2 Granulocyte Colony Stimulating Factor
5.3 Purified Proteins
5.3.1 Leukemia Inhibitory Factor (LIF)
5.3.2 P53 Protein
5.3.3 P38 Protein
5.4 Recombinant Proteins
5.4.1 Serum Albumin
5.4.2 Amyloid Protein
5.4.3 Defensin
5.4.4 Cyclase
5.4.5 Caspase
5.4.6 Cathepsin
5.5 Recombinant Hormones
5.5.1 Recombinant Human Growth Hormone (HGH)
5.5.2 Recombinant Insulin
5.6 Synthetic Immunomodulators
5.6.1 Cytokines, Interferons, Interleukins
5.6.2 Tumor Necrosis Factor (TNF)
5.7 Vaccines
5.7.1 Recombinant Vaccines
5.7.1.1 Cancer Vaccines
5.7.1.2 Malaria Vaccine
5.7.1.3 Ebola Vaccine
5.7.1.4 Hepatitis-B Vaccine
5.7.1.5 Tetanus vaccine
5.7.1.6 Diphtheria Vaccine
5.7.1.7 Cholera Vaccine
5.7.2 Conventional Vaccines
5.7.2.1 Polio Vaccine
5.7.2.2 Pox Vaccine
5.8 Recombinant Enzymes
5.8.1 Enterokinase
5.8.2 Transferrin
5.9 Others
5.9.1 Blood factors
6. The Middle East & Africa Biopharmaceuticals Market- By Therapeutic Application
6.1 Oncology
6.1.2 Inflammatory and Infectious Diseases
6.1.3 Autoimmune Disorders
6.1.4 Metabolic Disorders
6.1.5 Hormonal Disorders
6.1.6 Disease Prevention
6.1.7 Cardiovascular Diseases
6.1.8 Neurological Diseases
6.1.9 Other Diseases
7. The Middle East & Africa Biopharmaceuticals Market– By Country
7.1.Introduction
7.2.Egypt
7.3. Africa
7.4. Rest of Middle East & Africa
8. Company Profiles
8.1 Merck & Co
8.2 F. Hoffmann-La Roche AG
8.3 Eli Lilly and Company
8.4 Sanofi
8.5 Amgen Inc.
8.6 AbbVie Inc.
8.7 Biogen Idec
8.8 Bayer AG
8.9 Johnson & Johnson
8.10 Pfizer, Inc
8.11 Novartis AG
9. The Middle East & Africa Biopharmaceuticals Market– Competitive Landscape
9.1 Market Share Analysis
9.2 Strategies Adopted by top companies
9.3 Mergers, Acquisitions, Collaborations & Agreements
10. Market Insights
10.1 Insights of Industry Experts
10.2 Investment Opportunities
10.3 Analyst Opinion
11. Appendix
11.1 List of Tables
11.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Regional Report
$2,160.00 – $7,200.00
- EUR: €1,991.88 - €6,639.62
- INR: ₹180,043.09 - ₹600,143.64
- AED: د.إ7,927.20 - د.إ26,424.00
- GBP: £1,706.75 - £5,689.16
Description
Regional Reports
Additional information
Report Type | Extensive Report, Miniature report, Snapshot Report |
---|---|
Licence | Single User License, Team License, Corporate License |
Biopharmaceuticals are pharmaceutical products which are produced through biotechnology methods involving recombinant DNA techniques, hybridoma techniques, and purification processes. Biopharmaceutical production consists of the use of biological sources, either live organisms or their active components. They are made up of proteins and nucleic acids and target specific diseases and patients groups. Biopharmaceuticals are used in the treatment of various chronic diseases such as cardiovascular, metabolic, neurological, cancer, and other rare diseases for which there are no available treatments.
The Middle East & Africa Biopharmaceuticals Market Segments Size & Growth:
The Middle East & Africa Biopharmaceuticals market size is projected to reach approximately $23.80 billion by the end of 2024 with a CAGR of close to 9.16 % from $15.90 billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include High-profit margins, Huge market demand, Ability of Biopharmaceuticals to treat previously untreatable diseases, Increasing acceptance for Biopharmaceuticals and so on. However, High-end manufacturing requirements, Increasing demand for affordable Biopharmaceuticals and Complicated and Cumbersome regulatory requirements thereby hampering the market growth.
The Middle East & Africa Biopharmaceuticals Market Segments Share:
The Middle East & Africa Biopharmaceuticals Market is categorised into a type which comprises of Monoclonal antibodies, Recombinant growth factors, Purified proteins, Recombinant proteins, Recombinant hormones and so on. Among the Type, a Monoclonal antibodies market segment dominated the Biopharmaceuticals market in 2018 with about 32% share. By Therapeutic Applications, Biopharmaceuticals market is segregated into Neurological diseases, Cardiovascular diseases, Hormonal disorders and so on. Among the Therapeutic Applications, Oncology segment is projected to continue its dominant during the period 2018-2024. By Geography, Africa is expected to dominate the Biopharmaceuticals market and the growth in the Africa economies is mainly attributed because of huge profit margins and growth prospects, biopharmaceuticals have garnered the attention of several large drug development companies.
The Middle East & Africa Biopharmaceuticals Market Trends:
- Biopharmaceuticals currently represent a large segment of product pipelines of most of the major pharmaceutical companies.
- Monoclonal antibodies currently own the most significant market share regarding value in the global biopharmaceuticals market. Some of the top-selling monoclonal antibodies include Adalimumab, Infliximab, Rituximab, and Bevacizumab.
- Amgen is introducing an innovative new value-based pharmacy benefits insurance provision for U.S. staff members. The coverage ensures that any U.S. staff member who is prescribed a clinically appropriate biologic medicine will pay the same out-of-pocket cost as a staff member who has the same condition but does not require a biologic. The benefit was designed to eliminate concerns about cost-related barriers to essential biopharmaceuticals, which play an increasingly prominent role in the treatment of patients with acute illness.
The Middle East & Africa Biopharmaceuticals Market Research Report:
- An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
- To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
- Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
- Identifying DROC in the current market and their impact in altering the market dynamics.
- Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
- Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
- The primary market players, such as
- Merck & Co., Inc.
- Hoffmann-La Roche AG
- Eli Lilly and Company, Inc
- Sanofi
- Amgen Inc
1. Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
4. Market Dynamics
4.1 Drivers
4.1.1 High-profit margins
4.1.2 Huge market demand
4.1.3 Ability of Biopharmaceuticals to treat previously untreatable diseases
4.1.4 Increasing acceptance for Biopharmaceuticals
4.2 Restraints
4.2.1 Complicated and Cumbersome regulatory requirements
4.2.2 High-end manufacturing requirements
4.2.3 Increasing demand for affordable Biopharmaceuticals
4.3 Opportunities
4.3.1 Finding ways of cost reduction
4.3.2 Patent expiry paving the way for Biosimilars
4.4 Challenges
4.4.1 Requirement of cold chain
4.4.2 Scalability limited by several out of hand factors
4.4.3 Extremely difficult development process
5. The Middle East & Africa Biopharmaceuticals Market – By Type
5.1 Monoclonal Antibodies
5.1.1 Anti-Cancer Monoclonal Antibodies
5.1.2 Anti-Inflammatory Monoclonal Antibodies
5.1.3 Other Monoclonal Antibodies
5.2 Recombinant Growth Factors
5.2.1 Erythropoietin
5.2.2 Granulocyte Colony Stimulating Factor
5.3 Purified Proteins
5.3.1 Leukemia Inhibitory Factor (LIF)
5.3.2 P53 Protein
5.3.3 P38 Protein
5.4 Recombinant Proteins
5.4.1 Serum Albumin
5.4.2 Amyloid Protein
5.4.3 Defensin
5.4.4 Cyclase
5.4.5 Caspase
5.4.6 Cathepsin
5.5 Recombinant Hormones
5.5.1 Recombinant Human Growth Hormone (HGH)
5.5.2 Recombinant Insulin
5.6 Synthetic Immunomodulators
5.6.1 Cytokines, Interferons, Interleukins
5.6.2 Tumor Necrosis Factor (TNF)
5.7 Vaccines
5.7.1 Recombinant Vaccines
5.7.1.1 Cancer Vaccines
5.7.1.2 Malaria Vaccine
5.7.1.3 Ebola Vaccine
5.7.1.4 Hepatitis-B Vaccine
5.7.1.5 Tetanus vaccine
5.7.1.6 Diphtheria Vaccine
5.7.1.7 Cholera Vaccine
5.7.2 Conventional Vaccines
5.7.2.1 Polio Vaccine
5.7.2.2 Pox Vaccine
5.8 Recombinant Enzymes
5.8.1 Enterokinase
5.8.2 Transferrin
5.9 Others
5.9.1 Blood factors
6. The Middle East & Africa Biopharmaceuticals Market- By Therapeutic Application
6.1 Oncology
6.1.2 Inflammatory and Infectious Diseases
6.1.3 Autoimmune Disorders
6.1.4 Metabolic Disorders
6.1.5 Hormonal Disorders
6.1.6 Disease Prevention
6.1.7 Cardiovascular Diseases
6.1.8 Neurological Diseases
6.1.9 Other Diseases
7. The Middle East & Africa Biopharmaceuticals Market– By Country
7.1.Introduction
7.2.Egypt
7.3. Africa
7.4. Rest of Middle East & Africa
8. Company Profiles
8.1 Merck & Co
8.2 F. Hoffmann-La Roche AG
8.3 Eli Lilly and Company
8.4 Sanofi
8.5 Amgen Inc.
8.6 AbbVie Inc.
8.7 Biogen Idec
8.8 Bayer AG
8.9 Johnson & Johnson
8.10 Pfizer, Inc
8.11 Novartis AG
9. The Middle East & Africa Biopharmaceuticals Market– Competitive Landscape
9.1 Market Share Analysis
9.2 Strategies Adopted by top companies
9.3 Mergers, Acquisitions, Collaborations & Agreements
10. Market Insights
10.1 Insights of Industry Experts
10.2 Investment Opportunities
10.3 Analyst Opinion
11. Appendix
11.1 List of Tables
11.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Our Clientele
Exclusive Benefits
Credibility and Transparency
We actively recruit consumers, business professionals, and hard-to-reach individuals as members of our research panels, and we build trusted, ongoing relationships with them. Thus we provide the complete list of primary and secondary data sources in the report to maintain the transparency and to assure the credibility.
Exhaustive Coverage
Detailed and extensive coverage in the geography.Survey consultation for brand tracking, concept testing, consumer behaviour, and more, we have you covered with market research services that scale to meet your needs.
Competitive Edge
Our reports cover most recent updates in the market till the date of the purchase. We identify, gather and timely deliver analysis on impact of unprecedented decisions of CXOs in COVID-19 catastrophe on many businesses, their clients and their clients' clients without additional cost.
Golden Opportunities
A comprehensive strategic sieve analysis of the market by our analysts and consultants, aided by AI tools helps us find the non-obvious, golden and emerging opportunities for you to evaluate.
Top-notch Reports Guaranteed
70% of our research is exclusive; no other research firm has the depth and breadth of our research.
Post Purchase Support
Post-purchase support is provided for all our reports, for three months from the date of purchase, where related queries will be answered within 24 business hours over telephone or email.